ANGLE (ANPCY) Stock Price, News & Analysis

Company Overview

ANGLE plc is a United Kingdom–based biotechnology company specializing in the development and commercialization of liquid biopsy technologies for the capture and analysis of rare cells. The company’s principal offering, the Parsortix system, employs proprietary microfluidic instrumentation to isolate circulating tumor cells (CTCs) and other rare cell populations from blood samples without the need for labels. This platform is designed for both research and clinical applications, enabling downstream molecular and cellular analyses that support cancer diagnostics, prognostics and therapy monitoring.

ANGLE’s product portfolio comprises the Parsortix Harvest system and single-use cassettes, along with associated reagents and software for cell capture, imaging and data management. These consumables are optimized to deliver high capture efficiency while preserving cell viability and integrity, making them suitable for a range of analytical workflows including genomics, transcriptomics and cytology. The company continues to expand its pipeline of complementary reagents and protocols to address evolving needs in precision medicine research.

Founded in the early 2000s and headquartered in Guildford, England, ANGLE plc has established a commercial presence in Europe, North America and select markets in Asia through direct sales and distributor partnerships. The company works closely with academic institutions, pharmaceutical and biotechnology companies to integrate liquid biopsy solutions into clinical trials and translational research programs. ANGLE’s technology has been the subject of peer‐reviewed publications and presentations at international scientific conferences.

ANGLE plc is publicly traded on the London Stock Exchange’s AIM market and maintains an over‐the‐counter listing in the United States under the ticker ANPCY. The company’s leadership team combines expertise in bioengineering, oncology research and commercial strategy, guiding ANGLE’s efforts to drive adoption of non‐invasive diagnostics and support the development of next‐generation cancer therapies.

Key Stats

• Today's Range: C$0.26 to C$0.29
• 50-Day Range: C$0.26 to C$1.00
• 52-Week Range: C$0.26 to C$2.39
• Volume: 289 shs
• Average Volume: 2,173 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ANPCY Stock Analysis - Frequently Asked Questions

How have ANPCY shares performed this year?

ANGLE's stock was trading at C$1.35 at the beginning of 2025. Since then, ANPCY stock has decreased by 80.4% and is now trading at C$0.26.

How do I buy shares of ANGLE?

Shares of ANPCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ANPCY
• CIK: 1620678
• Web: www.angleplc.com
• Phone: 441483343434
• Fax: N/A
• Employees: 173
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A